Business
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenueMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively. “We finished the year with strong moment
About this update from Pacific Biosciences Of California, Inc.
[{"type":"image","alt":"PacBio","displaySize":"","headline":null,"caption":"PacBio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nO_Xed3UYAG.Z8cezVsIzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9","width":300,"height":263}},"lazy":false},{"type":"text","content":"Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenue","length":118,"tagName":"p"},{"type":"text","content":"MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively.","length":341,"tagName":"p"},{"type":"text","content":"“We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications,” said Christian Henry, President and CEO of PacBio. “In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Looking ahead, we believe that increased real-world evidence in the clinic, combined with the significantly lower costs enabled by SPRQ-Nx, will catalyze our next phase of growth in 2026 and beyond.”","length":551,"tagName":"p"},{"type":"text","content":"Fourth quarter and full year results:","length":37,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:52%;width:52%;min-width:52%;border-top:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:middle;text-align:left;padding-left:10.0px;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:12%;width:12%;min-width:12%;border-top:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"Q4 2025(Preliminary, unaudited)","length":33,...